Floatz logo

Cobolimab

Diffuse Intrinsic Pontine Glioma (DIPG)

GlaxoSmithKlinemonoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

27 Active assets in the Diffuse Intrinsic Pontine Glioma (DIPG) cohort.

Asset / SponsorPhaseRating
Irinotecan
Actuate Therapeutics Inc.
Phase 2BB
(+)-VINCRISTINE
Julie Krystal
Phase 2B
Valproic Acid
University of Göttingen
Phase 3B
Cyclophosphamide
Shenzhen Geno-Immune Medical Institute
Phase 2B
ETOPOSIDE
Theodore S. Johnson
Phase 2B

View all 42 →

Same molecule, other indications

Cobolimab is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
62 / 100
View asset →
adult hepatocellular carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
melanomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →